BELLUS Health Inc



PE Ratio
Market Cap
52 Week Range
$2.12 - $12.03
Operating Margin
Dividend & Yield
$0 (0.00%)
Rev. per Share

About BELLUS Health Inc

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. The company was founded in 1993 and is headquartered in Laval, Canada.


News about BELLUS Health Inc

Baystreet Canada
Wall Street Thinks This Stock Can Easily Double in Value
VOX Markets
last Wednesday
Blue Star Capital''s Derek Lew and John Meyer on Resource Companies with News - Vox Markets
The Straits Times
GRP Ltd director Mahtani Bhagwandas assisting with CAD probe
Business Wire
BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference
BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference - May 25, 2021
The Motley Fool Canada
Got $2,000? 4 Top Stocks to Buy This Month
Seeking Alpha
BELLUS Health (BLU) Investor Presentation - Slideshow
Smarter Analyst
BELLUS Health (BLU) Gets a Buy Rating from RBC Capital
BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
Dakota Financial News
BELLUS Health (NASDAQ:BLU) Releases Quarterly Earnings Results, Misses Estimates By $0.06 EPS

BELLUS Health Inc

About kinfo
Kinfo is an app for DIY traders and investors. Kinfo tracks your trading performance and lets you compare measurable performance metrics against other traders. Kinfo works for day trading, swing trading and longer holding periods. By tracking portfolio performance kinfo allows traders to learn, find inspiration and gain confidence.
Get Social
Download the App

Trading involves significant risk of loss. It is not suitable for all investors and you should make sure you understand the risks involved, seeking independent advice if necessary.

Never risk more than you are willing to lose. Trading futures and other derivatives may cause losses that exceed deposits.

Hypothetical performance results have inherent limitations, some of which are described below. Kinfo makes no representation that any trading account will or is likely to achieve profits or losses like those shown. There are often sharp differences between hypothetical trading performance results and the actual results subsequently achieved by any trading program. Past results of advertised trading systems, profit statements, charts or any other representations are not indicative of future performance.

Kinfo is an educational site and is not a financial adviser or broker. All stocks, ETFs, commodities, Indices, Forex, Bonds, and other securities mentioned in our courses are for educational and illustrative purposes only. If you need professional investment advice, please consult a registered investment adviser. Futures and Options carry risk and may not be suitable for everyone.

Kinfo demonstrates specific advanced approaches (or methods). Any mention of Return of Investment percentages is only indicative of the potential of the strategy or the system and is not meant to signify any guaranteed returns.

Success in trading involves a range of human factors like decision making skills, adjustment skills, emotional control, and risk management and other psychological and behavioral parameters, all of which are completely in the hands of the individual. Trading involves significant risk of loss. It is not suitable for all investors.

Charts on kinfo provided by TradingView